Research
Hormonal
Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.
Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.
StrongSupportsmedium confidence
Estimated change in mean (SD) percentage body weight from baseline to week 24 was -8.82 (4.94) with liraglutide, 3.0 mg (n = 31), vs -0.54 (3.32) with placebo (n = 26).
Why this rating
Based on a randomized placebo-controlled trial design.
Source
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery
Jessica Mok et al. · JAMA Surgery · 2023
rct · n=70Cited 148×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →